New Treatment Strategies and Epigenetic Biomarker for Management of BPH
NOT_YET_RECRUITING
Beth Israel Deaconess Medical Center
PHASE2
2025-10-01
SRD5A2 is a critical enzyme for prostatic development and growth, and the SRD5A2 inhibitor, finasteride, is used to treat benign prostatic hyperplasia (BPH). SRD5A2 is absent in 30% of normal adult men, which explains the resistance of a subset of patients to this commonly prescribed drug. This project proposes new combination therapies (5-ARI+raloxifene) and evaluates novel non-invasive biomarkers, based on alternative pathways that lead to prostatic enlargement.
SWOG-9346, Hormone Therapy in Treating Men With Stage IV Prostate Cancer
Completed
Cancer and Leukemia Group B
Phase 3
1995-05-01
RATIONALE: Testosterone can stimulate the growth of prostate cancer cells. Hormone therapy
may be effective treatment for prostate cancer. It is not yet known which regimen of hormone
therapy is most effective for stage IV prostate cancer.
PURPOSE: This randomized phase III trial is studying two different regimens of hormone
therapy and comparing how well they work in treating men with stage IV prostate cancer.
SWOG-9346, Hormone Therapy in Treating Men With Stage IV Prostate Cancer
Completed
Eastern Cooperative Oncology Group
Phase 3
1995-05-01
RATIONALE: Testosterone can stimulate the growth of prostate cancer cells. Hormone therapy
may be effective treatment for prostate cancer. It is not yet known which regimen of hormone
therapy is most effective for stage IV prostate cancer.
PURPOSE: This randomized phase III trial is studying two different regimens of hormone
therapy and comparing how well they work in treating men with stage IV prostate cancer.
SWOG-9346, Hormone Therapy in Treating Men With Stage IV Prostate Cancer
Completed
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3
1995-05-01
RATIONALE: Testosterone can stimulate the growth of prostate cancer cells. Hormone therapy
may be effective treatment for prostate cancer. It is not yet known which regimen of hormone
therapy is most effective for stage IV prostate cancer.
PURPOSE: This randomized phase III trial is studying two different regimens of hormone
therapy and comparing how well they work in treating men with stage IV prostate cancer.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
